AIM VACCINE (06660) plans to apply for an A-share listing on the Shenzhen Stock Exchange, aiming to become the first stock of "H+ North".

On the evening of March 30th, AIM VACCINE (06660) announced that the company has approved a resolution to increase domestic shares by no more than 40,000,000 shares, which is approximately 3.2611% of the total number of shares issued before this offering, and approximately 3.1582% of the total number of shares issued after this offering. Additionally, the company plans to apply for an A-share listing on the Beijing Stock Exchange. According to the listing rules of the Beijing Stock Exchange, the company's domestic shares must be listed on the National Equities Exchange and Quotations system. If AIM VACCINE's process goes smoothly, it is expected to become the first company to return from the Hong Kong Stock Exchange and list on the Beijing Stock Exchange, leading the way for Hong Kong-listed biopharmaceutical companies to list on the Beijing Stock Exchange. According to relevant data, CanSino Biologics Inc., also a vaccine company, has a valuation premium of up to 3.1 times in A shares compared to H shares. If AIM VACCINE achieves its "H+A" strategic layout, it will not only enhance the company's valuation and market activity, but also accelerate the development of its brand value and business. As the second largest vaccine group in China and the largest private vaccine group, AIM VACCINE is the only Chinese company with all five validated human vaccine technology platforms, each with products in clinical development. Several major products, including a serum-free iterative rabies vaccine, are in the final stages of market launch. In February of this year, AIM GLOBAL's self-developed serum-free iterative rabies vaccine successfully passed the on-site inspection of the National Medical Products Administration's clinical trial, and the inspection of the drug registration production site. This milestone indicates that the launch of this major product is closer, and the company's performance is expected to greatly improve. By accurately seizing the opportunity, the company's return to A shares at the turning point of performance explosion will greatly increase its attraction to investors.